Vinorelbine, also known by the brand name Navelbine, is a chemotherapy drug that has been tested as a second-line treatment for mesothelioma, both as a single agent and in combination with other drugs such as cisplatin or gemcitabine.
Written by Karen Selby, RN Edited By Walter Pacheco Medically Reviewed By Dr. Jeffrey Velotta
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family.LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Selby, K. (2023, March 23). Vinorelbine. Asbestos.com. Retrieved May 31, 2023, from https://www.asbestos.com/treatment/chemotherapy/vinorelbine/
Selby, Karen. "Vinorelbine." Asbestos.com, 23 Mar 2023, https://www.asbestos.com/treatment/chemotherapy/vinorelbine/.
Selby, Karen. "Vinorelbine." Asbestos.com. Last modified March 23, 2023. https://www.asbestos.com/treatment/chemotherapy/vinorelbine/.
What is Vinorelbine?
Vinorelbine belongs to a family of chemotherapy drugs known as vinca alkaloids, which were initially created from extracts of the periwinkle plant. The antitumor effects of this drug were discovered in 1959.
Vinorelbine is classified as an antineoplastic agent. It binds to microtubular proteins in cells. Microtubules are needed for cell reproduction, so damage to the microtubules by vinorelbine prevents cancer cells from reproducing and leads to their self-destruction.
- Other Names: Navelbine, vinorelbine tartrate
- Manufactured by: Pierre Fabre
- FDA-approved: Yes (to treat non-small cell lung cancer)
- Used or Tested in: Breast cancer, cervical cancer, esophageal cancer, Hodgkin lymphoma, Kaposi’s sarcoma, mesothelioma, non-small cell lung cancer, ovarian cancer, testicular cancer
Vinorelbine is typically administered in cycles of six weekly intravenous (IV) injections, though this varies based on the patient’s health factors and whether vinorelbine is combined with another chemotherapy drug.
Vinorelbine in Mesothelioma Treatment
Vinorelbine regimens are not as effective at extending survival as the standard pemetrexed and cisplatin treatment for mesothelioma. However, because vinorelbine has shown some effectiveness and has relatively low toxicity, doctors have continued to explore its value as a palliative or second-line therapy.
- Palliative Therapy: Vinorelbine can relieve symptoms and improve quality of life for mesothelioma patients who cannot tolerate other cancer therapies.
- Second-Line Therapy: Doctors may administer a regimen including vinorelbine to treat cancer reoccurrence after a patient has already received standard chemotherapy.
A 2017 review of second-line chemotherapy treatment for mesothelioma suggests even though international guidelines include vinorelbine as a suggested drug, the research evidence supporting its use is inconclusive.
In 2014, the Wales Cancer Trials Unit began a phase II clinical trial to further study the effectiveness of vinorelbine as a second-line treatment. The researchers also aim to determine whether the BRCA1 gene is required for vinorelbine to cause cancer-cell death.
A 2021 research study discovered that people with a BRCA1/MAD2L1 genetic deficiency may have decreased effectiveness with vinorelbine.
Side Effects of Vinorelbine
Common side effects include:
- Low red blood cell counts
- Low white blood cell counts
- Nausea and vomiting
- Muscle weakness
- Hair loss
- Mouth sores
Rare side effects include:
- Pain at the injection site
- Numbness or tingling in extremities
- Bruising and bleeding problems
- Blood in urine
- Abdominal pain
- Blood pressure changes